Pre-order Enquiry
Request Free Sample
Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2022
SKU ID : QYR-21195515 | Publishing Date : 01-Jul-2022 | No. of pages : 84
Detailed TOC of Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2022
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Exenatide
1.2.3 Liraglutide
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Perspective (2017-2028)
2.2 Peptide Based Metabolic Disorders Therapeutics Growth Trends by Region
2.2.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Peptide Based Metabolic Disorders Therapeutics Market Dynamics
2.3.1 Peptide Based Metabolic Disorders Therapeutics Industry Trends
2.3.2 Peptide Based Metabolic Disorders Therapeutics Market Drivers
2.3.3 Peptide Based Metabolic Disorders Therapeutics Market Challenges
2.3.4 Peptide Based Metabolic Disorders Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue
3.1.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide Based Metabolic Disorders Therapeutics Revenue
3.4 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Metabolic Disorders Therapeutics Revenue in 2021
3.5 Peptide Based Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.6 Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
3.7 Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Type
4.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028)
5 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Application
5.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028)
6.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
6.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028)
7.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
7.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028)
9.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.1.5 AstraZeneca Recent Development
11.2 Ingro Finanz (Bachem)
11.2.1 Ingro Finanz (Bachem) Company Detail
11.2.2 Ingro Finanz (Bachem) Business Overview
11.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Introduction
11.2.4 Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.2.5 Ingro Finanz (Bachem) Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Introduction
11.3.4 Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.3.5 Eli Lilly Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Detail
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Introduction
11.4.4 Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.4.5 Ipsen Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Introduction
11.5.4 Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.5.5 Merck Recent Development
11.6 Novo Nordisk
11.6.1 Novo Nordisk Company Detail
11.6.2 Novo Nordisk Business Overview
11.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Introduction
11.6.4 Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.6.5 Novo Nordisk Recent Development
11.7 PolyPeptide Group
11.7.1 PolyPeptide Group Company Detail
11.7.2 PolyPeptide Group Business Overview
11.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Introduction
11.7.4 PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.7.5 PolyPeptide Group Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Detail
11.8.2 Teva Pharmaceutical Business Overview
11.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Introduction
11.8.4 Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
11.8.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2022
List of TablesTable 1. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Exenatide
Table 3. Key Players of Liraglutide
Table 4. Key Players of Others
Table 5. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2017-2022)
Table 9. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2023-2028)
Table 11. Peptide Based Metabolic Disorders Therapeutics Market Trends
Table 12. Peptide Based Metabolic Disorders Therapeutics Market Drivers
Table 13. Peptide Based Metabolic Disorders Therapeutics Market Challenges
Table 14. Peptide Based Metabolic Disorders Therapeutics Market Restraints
Table 15. Global Peptide Based Metabolic Disorders Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players (2017-2022)
Table 17. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2021)
Table 18. Ranking of Global Top Peptide Based Metabolic Disorders Therapeutics Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
Table 22. Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2017-2022)
Table 26. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2023-2028)
Table 28. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2017-2022)
Table 30. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2023-2028)
Table 32. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 42. AstraZeneca Company Detail
Table 43. AstraZeneca Business Overview
Table 44. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product
Table 45. AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 46. AstraZeneca Recent Development
Table 47. Ingro Finanz (Bachem) Company Detail
Table 48. Ingro Finanz (Bachem) Business Overview
Table 49. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product
Table 50. Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 51. Ingro Finanz (Bachem) Recent Development
Table 52. Eli Lilly Company Detail
Table 53. Eli Lilly Business Overview
Table 54. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product
Table 55. Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 56. Eli Lilly Recent Development
Table 57. Ipsen Company Detail
Table 58. Ipsen Business Overview
Table 59. Ipsen Peptide Based Metabolic Disorders Therapeutics Product
Table 60. Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 61. Ipsen Recent Development
Table 62. Merck Company Detail
Table 63. Merck Business Overview
Table 64. Merck Peptide Based Metabolic Disorders Therapeutics Product
Table 65. Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Novo Nordisk Company Detail
Table 68. Novo Nordisk Business Overview
Table 69. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product
Table 70. Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 71. Novo Nordisk Recent Development
Table 72. PolyPeptide Group Company Detail
Table 73. PolyPeptide Group Business Overview
Table 74. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product
Table 75. PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 76. PolyPeptide Group Recent Development
Table 77. Teva Pharmaceutical Company Detail
Table 78. Teva Pharmaceutical Business Overview
Table 79. Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Product
Table 80. Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
Table 81. Teva Pharmaceutical Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Exenatide Features
Figure 3. Liraglutide Features
Figure 4. Others Features
Figure 5. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application in 2021 & 2028
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Metabolic Disorders Therapeutics Report Years Considered
Figure 10. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Peptide Based Metabolic Disorders Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region: 2021 VS 2028
Figure 13. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players in 2021
Figure 14. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue in 2021
Figure 16. North America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
Figure 18. United States Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
Figure 22. Germany Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2017-2028)
Figure 30. China Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
Figure 38. Mexico Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
Figure 42. Turkey Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. AstraZeneca Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 45. Ingro Finanz (Bachem) Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 46. Eli Lilly Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 47. Ipsen Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 48. Merck Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 49. Novo Nordisk Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 50. PolyPeptide Group Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 51. Teva Pharmaceutical Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Keyplayers in Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2022
AstraZenecaIngro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical
Request Sample
Request Discount
